Evidence map›Paper›PMID 27713401›Full record

ArticleCancer gene therapy2016

Synergism between RIZ1 gene therapy and paclitaxel in SiHa cervical cancer cells.

H Y Cheng, T Zhang, Y Qu, W J Shi, G Lou, Y X Liu, Y Y Zhang, L Cheng

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Synthesis of Pyrrolo[3,4-Molecules (Basel, Switzerland) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

H Y ChengDepartment of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
T ZhangDepartment of Gynecologic Oncology, The Red Flag Hospital of Mudanjiang Medical School, Heilongjiang, China.
Y QuDepartment of Gynecologic Oncology, The Traditional Chinese and Western Medicine Hospital of Fengtai District, Beijing, China.
W J ShiDepartment of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
G LouDepartment of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
Y X LiuDepartment of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
Y Y ZhangDepartment of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
L ChengDepartment of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CNMudanjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RIZ1 is a tumor suppressor gene. The purpose of the present study was to investigate the inhibitory effect of RIZ1 gene therapy on the growth of SiHa cervical cancer cells and its synergism with paclitaxel. The expression levels of RIZ1 were examined by real-time PCR and western blotting before and after transfection of RIZ1. The effects of paclitaxel or pcDNA3.1(+)-RIZ1 alone or in combination, on the proliferation of SiHa cells were evaluated by MTT method. The inhibitory effect on the proliferation of SiHa cells was more significant in the pcDNA3.1(+)-RIZ1 combined with paclitaxel group than in the pcDNA3.1(+)-RIZ1 or paclitaxel groups (P<0.05). The expression level of RIZ1 in SiHa cells increased after treatment with paclitaxel, which indicated a synergism between them. RIZ1 gene therapy combined with paclitaxel showed stronger cell inhibition than paclitaxel alone, which indicated a synergism between them.

Indexed as

Antineoplastic Agents, PhytogenicCell Line, TumorCell ProliferationCombined Modality TherapyDNA-Binding ProteinsFemaleGene ExpressionGenes, Tumor SuppressorGenetic TherapyHistone-Lysine N-MethyltransferaseHumansNuclear ProteinsPaclitaxelTranscription FactorsUterine Cervical NeoplasmsAntineoplastic Agents, PhytogenicDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseNuclear ProteinsPaclitaxelPRDM2 protein, humanTranscription Factors

Identifiers

PMID27713401
OpenAlexW2528158728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.